» Articles » PMID: 29434947

Association Between Inflammation and Cancer Stem Cell Phenotype in Breast Cancer

Overview
Journal Oncol Lett
Specialty Oncology
Date 2018 Feb 14
PMID 29434947
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Inflammation and cancer stem cells (CSCs) are becoming increasingly recognized as components of tumorigenesis in breast cancer. In the present study, the association between inflammation and BCSC phenotype was evaluated in human breast cancer tissue. Immunohistochemical staining for cluster of differentiation (CD)24, 44, 4, 8 and 68 was performed using tissue microarray blocks containing 47 consecutive cases of invasive breast carcinoma and 10 normal breast tissue samples. The levels of inflammatory modulators and cytokines, and intratumoral or peritumoral lymphocyte infiltration, were assessed. BCSCs were defined as CD44/CD24 tumor cells. In total, 21.3% of samples exhibited the CD44/CD24 phenotype. This phenotype was identified to be significantly inversely associated with lymph node metastasis. In addition, the CD44/CD24 phenotype was significantly associated with the molecular subtype of breast cancer, and was particularly increased in the basal-like subtype. Furthermore, the CD44/CD24 phenotype was significantly associated with intratumoral inflammation and tumor-infiltrating CD4 T cell counts. Notably, tumor-infiltrating CD4 T cells were significantly increased in patients with the basal-like molecular subtype of breast cancer. In conclusion, the present study identified a significant association between inflammation and the CD44/CD24 phenotype in breast cancer. These results suggest that the interaction between inflammation and CSCs may affect the tumorigenesis and progression of breast cancer. Further studies are required to clarify the role of inflammation and CSCs in breast cancer.

Citing Articles

Short-Term Changes in TNF-Alpha, IL-6 and Adiponectin Following Bariatric Surgery in Caucasian Obese Adults: An Observational Case-Control Study.

Ion R, Hutanu A, Sala D, Muresan M, Fodor S, Voidazan S Medicina (Kaunas). 2024; 60(11).

PMID: 39596974 PMC: 11596550. DOI: 10.3390/medicina60111789.


The Role of Cancer and Somatic Stem Cells in the Anti-Inflammatory and Antitumor Effects of Aconitum baicalense Extract on Experimental Breast Cancer.

Pershina O, Ermakova N, Pakhomova A, Zhukova M, Pan E, Sandrikina L Bull Exp Biol Med. 2023; 175(2):254-259.

PMID: 37466854 DOI: 10.1007/s10517-023-05845-8.


Cancer Stem Cell Relationship with Pro-Tumoral Inflammatory Microenvironment.

Sipos F, Muzes G Biomedicines. 2023; 11(1).

PMID: 36672697 PMC: 9855358. DOI: 10.3390/biomedicines11010189.


Metabolic Plasticity of Cancer Stem Cells in Response to Microenvironmental Cues.

Xie Y, Ma S, Tong M Cancers (Basel). 2022; 14(21).

PMID: 36358763 PMC: 9657081. DOI: 10.3390/cancers14215345.


The Relationship between Cancer and Paraoxonase 1.

Medina-Diaz I, Ponce-Ruiz N, Rojas-Garcia A, Zambrano-Zargoza J, Bernal-Hernandez Y, Gonzalez-Arias C Antioxidants (Basel). 2022; 11(4).

PMID: 35453382 PMC: 9028432. DOI: 10.3390/antiox11040697.


References
1.
Iqbal J, Chong P, Tan P . Breast cancer stem cells: an update. J Clin Pathol. 2013; 66(6):485-90. DOI: 10.1136/jclinpath-2012-201304. View

2.
Abraham B, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H . Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res. 2005; 11(3):1154-9. View

3.
Jiang X, Ellison S, Alarid E, Shapiro D . Interplay between the levels of estrogen and estrogen receptor controls the level of the granzyme inhibitor, proteinase inhibitor 9 and susceptibility to immune surveillance by natural killer cells. Oncogene. 2007; 26(28):4106-14. DOI: 10.1038/sj.onc.1210197. View

4.
Boyle S, Kochetkova M . Breast cancer stem cells and the immune system: promotion, evasion and therapy. J Mammary Gland Biol Neoplasia. 2014; 19(2):203-11. DOI: 10.1007/s10911-014-9323-y. View

5.
Goldberg J, Schwertfeger K . Proinflammatory cytokines in breast cancer: mechanisms of action and potential targets for therapeutics. Curr Drug Targets. 2010; 11(9):1133-46. DOI: 10.2174/138945010792006799. View